The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | MRD-guided maintenance discontinuation in myeloma: long-term results from GEM2014MAIN
David Moreno, MD, PhD, Hospital Clinic Barcelona, Barcelona, Spain, discusses long-term results from the GEM2014MAIN study (NCT02406144) evaluating measurable residual disease (MRD)-guided discontinuation of maintenance therapy in newly diagnosed multiple myeloma. He highlights the association between MRD negativity and prolonged progression-free survival, including outcomes after treatment discontinuation, and the potential for sustained MRD negativity to help identify patients who may achieve long-term disease control without ongoing maintenance. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
